{"id":"azathioprine-or-methotrexate","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Myelosuppression (leukopenia, thrombocytopenia)"},{"rate":"10-20%","effect":"Nausea and vomiting"},{"rate":"5-15%","effect":"Hepatotoxicity"},{"rate":"5-10%","effect":"Infection"},{"rate":"5-10%","effect":"Mucositis"},{"rate":"5-10%","effect":"Alopecia"},{"rate":"1-3%","effect":"Pancreatitis (azathioprine)"}]},"_chembl":{"chemblId":"CHEMBL1542","moleculeType":"Small molecule","molecularWeight":"277.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azathioprine is a purine analog prodrug that is converted to 6-mercaptopurine, which inhibits purine synthesis and reduces T-cell and B-cell proliferation. Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, blocking DNA synthesis and cell division. Both drugs suppress immune responses and are used to control inflammatory and autoimmune conditions.","oneSentence":"Azathioprine and methotrexate are immunosuppressive agents that inhibit cell proliferation and reduce immune activation by interfering with nucleotide synthesis and cellular metabolism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:26.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Rheumatoid arthritis"},{"name":"Autoimmune hepatitis"},{"name":"Systemic lupus erythematosus"},{"name":"Vasculitis"}]},"trialDetails":[{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT07290803","phase":"","title":"This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-17","conditions":"Atopic Dermatitis","enrollment":1000},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT05689879","phase":"PHASE3","title":"Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-23","conditions":"Sarcoidosis","enrollment":90},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT03760003","phase":"PHASE2","title":"Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-08-13","conditions":"Ulcerative Colitis","enrollment":355},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT04972760","phase":"PHASE3","title":"Baricitinib in Patients With Relapsing or naïve Dermatomyositis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-08-31","conditions":"Dermatomyositis","enrollment":62},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT04871191","phase":"PHASE3","title":"Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03","conditions":"Granulomatosis with Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":42},{"nctId":"NCT02852694","phase":"PHASE4","title":"Reduce Risk for Crohn's Disease Patients","status":"COMPLETED","sponsor":"PIBD-Net","startDate":"2017-02-28","conditions":"Crohn's Disease","enrollment":192},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT05458531","phase":"","title":"Monitoring of Inflammatory Conditions","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2022-06-28","conditions":"Inflammatory Disease, Crohn Disease, Ulcerative Colitis","enrollment":664},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":"Eye Diseases, Uveitis","enrollment":15},{"nctId":"NCT05263505","phase":"PHASE2","title":"Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2022-02-21","conditions":"Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis","enrollment":2},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT05386290","phase":"","title":"A Multicentered Prospective Cohort Study of Chinese IBD Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-09","conditions":"Ulcerative Colitis, Crohn Disease","enrollment":200},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT04124861","phase":"NA","title":"Withdraw Drug in Stable IgG4-Related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-06-23","conditions":"Autoimmune Diseases","enrollment":138},{"nctId":"NCT05078294","phase":"","title":"Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2021-08-01","conditions":"Dermatitis, Atopic","enrollment":300},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT00539838","phase":"PHASE3","title":"A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-12-19","conditions":"Systemic Lupus Erythematosus","enrollment":33},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02413047","phase":"NA","title":"Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator","status":"TERMINATED","sponsor":"Indiana University","startDate":"2015-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease","enrollment":3},{"nctId":"NCT04109300","phase":"NA","title":"Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2020-09-01","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":162},{"nctId":"NCT03553472","phase":"","title":"Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-01","conditions":"Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease","enrollment":97},{"nctId":"NCT03889808","phase":"","title":"Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2014-03","conditions":"Clostridium Difficile, Inflammatory Bowel Diseases","enrollment":500},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT02434133","phase":"","title":"Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-04","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":110},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01033656","phase":"PHASE2","title":"Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"2005-12","conditions":"Adult-Onset Still's Disease","enrollment":23},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT01802593","phase":"PHASE4","title":"Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure","status":"TERMINATED","sponsor":"Prof. Arie Levine","startDate":"2013-02","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT02188017","phase":"PHASE4","title":"Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2014-06","conditions":"Sarcoidosis, Pulmonary Sarcoidosis","enrollment":20},{"nctId":"NCT01446211","phase":"PHASE3","title":"Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis","status":"TERMINATED","sponsor":"Nordic Pharma SAS","startDate":"2011-11","conditions":"Wegeners Granulomatosis","enrollment":4},{"nctId":"NCT00546546","phase":"PHASE4","title":"Early Immunosuppressants in Crohn's Disease","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2005-07","conditions":"Crohn's Disease","enrollment":120},{"nctId":"NCT00987831","phase":"PHASE1, PHASE2","title":"Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2009-05","conditions":"Systemic Lupus Erythematosus","enrollment":158},{"nctId":"NCT00720798","phase":"PHASE3","title":"An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":2067},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT01813617","phase":"","title":"Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2010-09","conditions":"Polymyositis, Dermatomyositis","enrollment":72},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00307671","phase":"PHASE4","title":"Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-07","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":108},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00554710","phase":"PHASE4","title":"Top Down Versus Step Up Strategies in Crohn's Disease","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2001-05","conditions":"Crohn's Disease","enrollment":129},{"nctId":"NCT00349674","phase":"PHASE3","title":"WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1999-01","conditions":"Systemic Wegener's Granulomatosis","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76905,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["6 MERCAPTOPURINE"],"phase":"marketed","status":"active","brandName":"AZATHIOPRINE or METHOTREXATE","genericName":"AZATHIOPRINE or METHOTREXATE","companyName":"Prof. Arie Levine","companyId":"prof-arie-levine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azathioprine and methotrexate are immunosuppressive agents that inhibit cell proliferation and reduce immune activation by interfering with nucleotide synthesis and cellular metabolism. Used for Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Rheumatoid arthritis, Autoimmune hepatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}